This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Molecular Diagnostics Veteran, Greg Richard, Joins PDI, Inc. As General Manager For Interpace Diagnostics Subsidiary

PARSIPPANY, N.J., April 2, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a market leader in healthcare product commercialization and integrated marketing services, has hired Greg Richard as General Manager for its Interpace Diagnostics subsidiary. Richard will be responsible for evolving and driving the execution of PDI's molecular diagnostics growth strategy. 

Molecular Diagnostics Industry Veteran Greg Richard Joined PDI, Inc. as General Manager, Interpace Diagnostics, on April 2, 2014.

"Molecular Diagnostics is a fast-growing market that represents a significant opportunity for PDI," said Nancy Lurker, chief executive officer of PDI, Inc. "Greg's dynamic experience in developing strategy, driving revenue growth and his relationships with payers in molecular diagnostics is exactly what we sought to help PDI execute our long term strategic vision."

Mr. Richard has more than 20 years of successful experience in sales, marketing and managed care with life science companies ranging from Fortune 500 to small, privately held organizations. He joins PDI from Strata Pathology Services, where he restructured and grew the anatomical pathology sales organization and worked to expand the Company's geographic presence.

He was previously Executive Vice President of Sales and Marketing at Signal Genetics, a New York-based start-up molecular diagnostics company, where he built a new sales team and launched the company's two proprietary molecular oncology tests. Earlier in his career, Richard was Northeast Vice President of Sales for LabCorp, with responsibility for physician sales of the company's routine and molecular diagnostics (esoteric) testing services and a team of 150 reps with $1 billion in revenues, and spent eight years with Quest Diagnostics where he reached the level of Vice President, Health Plan and Payor Markets.

Mr. Richard will oversee Interpace Diagnostics' operations, business development, sales and marketing functions. His responsibilities include the identification and establishment of new molecular diagnostics commercialization partnerships and managed care strategy development, and he will be a member of PDI's Executive Committee.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs